Allergan shares jump after Morgan Stanley says fears of a 'better Botox' are overdone [CNBC]
Revance Therapeutics, Inc. (RVNC)
Last revance therapeutics, inc. earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.revance.com
Company Research
Source: CNBC
Shares of Allergan jumped more than 2 percent Wednesday after analysts at Morgan Stanley downplayed concern over competitive pressure for its key product, Botox. Fears about a 'better Botox' may be overdone, said analyst David Risinger in a note to clients. He noted that it could be difficult for competitor Revance Therapeutics to show that its Botox-like product — botulinum toxin RT002 — is materially longer-lasting than Botox, which has been a concern for AGN investors. Allergan shares are down 23 percent over the past three months, while Revance's stock is up 7.4 percent in that time period. But Morgan Stanley upgraded the stock to overweight from equal weight and maintained its $200 per share price target, which is 16.3 percent higher than Tuesday's closing price. We also think that mechanistically it would be difficult to create a significantly longer-lasting Botox because botulinum toxin gradually loses efficacy over four months due to neuronal regenera
Show less
Read more
Impact Snapshot
Event Time:
RVNC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVNC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVNC alerts
High impacting Revance Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RVNC
News
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Spirair, Developer of the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation, Announces Appointment of Benjamin Bishop as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Global Cell Penetrating Peptide Market to Reach $8.40 Billion by 2030 Owing To Increasing Demand for Targeted Drug Delivery Systems | Says Coherent Market Insights [Yahoo! Finance]Yahoo! Finance
- Revance Announces Pricing of $100.0 Million Public Offering of Common StockBusiness Wire
RVNC
Earnings
- 2/28/24 - Beat
RVNC
Sec Filings
- 3/21/24 - Form DEFA14A
- 3/21/24 - Form DEF
- 3/19/24 - Form 4
- RVNC's page on the SEC website